Vaxdyn Readies Vaccines To Target AMR Bacteria
First Spanish Biotech To Get CARB-X Funding
Executive Summary
Emerging Company Profile: Multi-valent vaccine developer Vaxdyn has become the first Spanish biotech to be funded by CARB-X and will use the money to help fund a trivalent jab for use against the world’s three most dangerous drug-resistant bacteria.